Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 270 participants.

Also called NCT06202378

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 270 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06202378
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06202378. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-29 (actual); primary completion 2024-11-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
3 ampoules of SHPL-49 Injection
Intervention (Drug)
6 ampoules of SHPL-49 Injection
Intervention (Drug)
0.9% Sodium Chloride Injection
Lead sponsor
Shanghai Hutchison Pharmaceuticals Limited (class: industry)
Collaborator
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct06202378
Content hash
f11806900905de9602302e573152c7e7666c6d96966a11fd7bee534c452dfc5a